These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 11772158)

  • 1. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.
    Limat S; Woronoff-Lemsi MC; Menat C; Madroszyk-Flandin A; Merrouche Y
    Pharmacoeconomics; 2004; 22(10):633-41. PubMed ID: 15244489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic review.
    Coukell AJ; Noble S; Faulds D
    Pharmacoeconomics; 1999 Apr; 15(4):405-17. PubMed ID: 10537959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
    Messori A; Trippoli S; Becagli P; Tendi E
    Cancer; 1996 Dec; 78(11):2366-73. PubMed ID: 8941008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomic profile of taxanes in advanced ovarian cancer.
    Messori A; Trippoli S
    Anticancer Drugs; 1998 Nov; 9(10):909-16. PubMed ID: 9890702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
    Lamb HM; Wiseman LR
    Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.
    McGuire W; Neugut AI; Arikian S; Doyle J; Dezii CM
    J Clin Oncol; 1997 Feb; 15(2):640-5. PubMed ID: 9053488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
    Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
    Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
    Wiseman LR; Spencer CM
    Drugs Aging; 1998 Apr; 12(4):305-34. PubMed ID: 9571394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacoeconomics of cancer therapies.
    Bishop JF; Macarounas-Kirchman K
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
    Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
    Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.
    Dranitsaris G; Elia-Pacitti J; Cottrell W
    Pharmacoeconomics; 2004; 22(6):375-87. PubMed ID: 15099123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
    Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
    Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.
    Elit LM; Gafni A; Levine MN
    J Clin Oncol; 1997 Feb; 15(2):632-9. PubMed ID: 9053487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.